EICHORCondition: Non-Small Cell Lung Cancer · Sponsor: Summit Therapeutics
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
This description comes directly from the study's public registry record.
Summit Clinical Trial Information · 1-833-256-0522 · medicalinformation@smmttx.com
Always discuss trial participation with your own doctor first.
| Clinical Study Site | Chandler, Arizona, United States | Recruiting |
| Clinical Study Site | Phoenix, Arizona, United States | Recruiting |
| Clinical Study Site | Hot Springs, Arkansas, United States | Recruiting |
| Clinical Study Sites | Jonesboro, Arkansas, United States | Recruiting |
| Clinical Study Site | Alameda, California, United States | Recruiting |
| Clinical Study Site | Anaheim, California, United States | Recruiting |
| Clinical Study Site | Beverly Hills, California, United States | Recruiting |
| Clinical Study Site | Cerritos, California, United States | Recruiting |
| Clinical Study Site | Los Angeles, California, United States | Recruiting |
| Clinical Study Site | Los Angeles, California, United States | Recruiting |
| Clinical Study Site | Orange, California, United States | Recruiting |
| Clinical Study Site | Oxnard, California, United States | Recruiting |
+ 258 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06767514